Enterome presents strengthened interim Phase 2 results for lead OncoMimics(TM) immunotherapy EO2463 to treat follicular lymphoma at ASH
New data show 100% (6/6) objective response rate (ORR) with EO2463 in previously untreated patients with follicular lymphoma needing treatment in combination with rituximab (SIDNEY Cohort 3) Of the 6 patients, 5 had a complete response (CR), 1 partial response (PR) Patients with follicular lymphoma in watch-and-wait setting (SIDNEY Cohort 2) showed a 52.6% ORR […]